Document is current

Any future updates will be listed below

Correction to: Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial

Crossref DOI link: https://doi.org/10.1007/s00125-024-06095-7

Published Online: 2024-02-13

Published Print: 2024-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark